Home  |  Top News  |  Most Popular  |  Video  |  Multimedia  |  News Feeds  |  Feedback
  Medicine  |  Nature & Earth  |  Biology  |  Technology & Engineering  |  Space & Planetary  |  Psychology  |  Physics & Chemistry  |  Economics  |  Archaeology
Top > Medicine, Health Care > Joslin Scientists Find That Salsalate… >

Joslin Scientists Find That Salsalate Lowers Blood Glucose in Type 2 Diabetes

Published: July 2, 2013.
Released by Joslin Diabetes Center  

BOSTON – July 1, 2013 -- Joslin scientists report that salsalate, a drug used to treat arthritis, lowers blood glucose and improves glycemic control in type 2 diabetes. These findings, which were published today by the Annals of Internal Medicine, provide additional evidence that salsalate may be an effective drug to treat type 2 diabetes.

The scientists became interested in studying salsalate, an anti-inflammatory drug, after research conducted by Steven Shoelson, M.D., Ph.D., Head of the Section on Pathophysiology and Molecular Pharmacology and Professor of Medicine at Harvard Medical School, identified inflammation as a factor in the development of type 2 diabetes.

Stage 1 of TINSAL-T2D (Targeting Inflammation Using Salsalate in Type 2 Diabetes) evaluated varying doses of salsalate in 108 participants with type 2 diabetes for 14 weeks. This study was reported in the Annals of Internal Medicine in 2010. The current findings are based on Stage 2 of TINSAL-T2D, which evaluated 286 participants with type 2 diabetes for 48 weeks. The subjects' blood glucose was inadequately controlled on current diabetes medications. Participants were randomized into salsalate and placebo groups.

After 48 weeks of treatment, the mean hemoglobin A1c level (a measurement of average blood glucose control over the past six to twelve weeks) was 37 percent lower in the salsalate group compared to the placebo group. The decrease in fasting glucose concentration was 15 mg/dl greater in the salsalate group than the placebo group. Patients in the salsalate group required fewer additional diabetes medications to control their blood sugar than patients in the placebo group.

"It's exciting that salsalate is effective in lowering blood sugar," says Allison Goldfine, M.D., lead author and Head of the Section of Clinical, Behavioral and Outcomes Research, and an Associate Professor of Medicine at Harvard Medical School. "Salsalate may have an important role in diabetes treatment and may also help us learn more about how inflammation contributes to the development of type 2 diabetes."

The salsalate group also showed improvements in markers associated with coronary risk: a 9 percent reduction in triglycerides and a 27 percent increase in adiponectin, a potentially cardioprotective protein from adipocytes. Uric acid, which is associated with cardiometabolic conditions and progression of renal disease, decreased 18 percent in the salsalate group. "The reductions in these cardiovascular risk factors paralleled improved glycemia," says Dr. Goldfine. However, the salsalate group also exhibited modest increases in LDL cholesterol and urine albumin, and had a slight increase in weight, which can indicate negative effects on heart or kidney function.

Salsalate's anti-inflammatory effects were evidenced by reductions in circulating white blood cells, neutrophils and lymphocytes, which are elevated in obesity and metabolic syndrome, but all remained within normal range.

The next step in determining whether salsalate is a safe drug for use as a diabetes medication and can receive FDA approval is to assess its effects on the progression of heart disease. Dr. Goldfine is currently leading a study, TINSAL-CVD, which is evaluating how salsalate affects coronary artery plaque volume in participants with established coronary artery disease. The results should be available in two years. "The study will help us better understand the risk/benefit ratio of using salsalate to treat diabetes," says Dr. Goldfine.




The above story is based on materials provided by Joslin Diabetes Center.

Translate this page: Chinese French German Italian Japanese Korean Portuguese Russian Spanish


comments powered by Disqus


Related »

Type 
5/27/11 
★★ 
Super-sticky 'Ultra-bad' Cholesterol Revealed in People at High Risk of Heart Disease
Scientists from the University of Warwick have discovered why a newly found form of cholesterol seems to be 'ultra-bad', …
Risk 
5/15/14 
Significant Differences in CVD Risk Factors Between Men And Women with Type 2 Diabetes
New Rochelle, NY, May 15, 2014—Type 2 diabetes greatly increases a person's risk of developing cardiovascular disease (CVD). A …
Ldl-C 
6/13/14 
Are the New ACC/AHA Guidelines for Lipids Appropriate for People with Diabetes?
June 13, 2014 (San Francisco) – New guidelines for the treatment of high cholesterol are not appropriate for people …
Diabetes 
11/14/12 
ESC Says Don't Forget to Screen for Diabetes in CAD Patients
Sophia Antipolis, 14 November 2012: While it is well recognized that patients with diabetes are at risk of developing …
Statins 
9/10/14 
The Lancet Diabetes & Endocrinology: Study Indicates That Statins May Protect Against Microvascular Complications of Diabetes
The development of common diabetes complications* that can lead to blindness and amputations could be reduced by taking statins, …
Troponin 
9/10/14 
A New Way to Look at Diabetes And Heart Risk
People with diabetes who appear otherwise healthy may have a six-fold higher risk of developing heart failure regardless of …
Blood 
12/19/14 
People with Blood Groups A, B And AB at Higher Risk of Type 2 Diabetes Than Group O
A study of more than 80,000 women has uncovered different risks of developing type 2 diabetes associated with different …
Acid 
12/20/10 
Component in Common Dairy Foods May Cut Diabetes Risk
Boston, MA – Scientists at the Harvard School of Public Health (HSPH) and collaborators from other institutions have identified …
More » 
 
© Newsline Group  |  About  |  Privacy Policy  |  Feedback  |  Mobile